VistaGen Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of VTGN for the last quarter is 411.40 k USD, and it's 48.15% higher compared to the previous quarter. The net income of Q3 23 is -6.35 M USD.